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In a single-blind study lasting 6 months an entirely new
anti-anginal preparation, perhexiline maleate (Pexid), was
prescribed in a dose of 200 mg b.d. to 21 patients suf-
fering from angina pectoris.
There was a statistically significant reduction in the
average number of anginal attacks over the 6-month
period in each subgroup studied. Half the cases studied
were asymptomatic at the end of the period. Side-effects
were reported in 16 patients; dizziness, headache, weak-
ness, loss of weight and decreased libido being the com-
monest symptoms. No patient withdrew from th~ trial
because of these symptoms, which disappeared within 4
weeks of continued therapy.
S. Afr. Med. l., 48, 904 (1974).
Perhexiline maleate (Pexid) is an entirely new cardio-
vascular drug with the chemical formula:
2-(2,2 dicyclohexylethyl)-piperidine maleate.
It is not a beta-blocking agent and its actions in
experimental work appear to be vasodilatation of the
systemic and coronary arterial systems, with increased
coronary blood flow; a reduction of left ventricular work;
slowing of the exercise-induced tachycardia only; and a
sustained bronchodilatation and diuretic effect.'" The ac-
tion of the drug is not fully understood but is not due to
beta blockade or the inhibition of adenosine deaminase
activity. It is unrelated chemically to any drug at present
used in the management of angina pectoris.
Slowing of the exercise-induced heart rate by perhexiline
is due to a direct action on the sino-atrial node. Animal
studies indicate that this preparatIon has a quinidine-like
action on the cardiac membrane and causes prolongation
of both depolarisation and repolarisation times.3
The effects of the preparation on left ventricular func-
tion in man were recently determined and, using
catheter techniques in patients with angma pectoris, to
whom perhexiline had been orally administered for 2
weeks, it was found to cause a slight decrease in cardiac
index without depressing left ventricul:tr function. Both
at rest and during tachycardia, there was improved
oxygen extraction as well as improved lactate extraction.'
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Several clinical studies of the effects of perhexiline have
been reported;" and this preparation was shown to
considerably reduce the incidence of anginal symptoms.
Recent work also suggests that this preparation may
have anti-arrhythmic effects in the human, particularly
in relation to ventricular extrasystoles'
Following an earlier assessment of a double-blind
crossover trial with perhexiline maleate' in the manage-
ment of angina,' referred to in the text as Trial 1, a long-
term continuous perhexiline maleate administration study
was embarked upon. The main aim of this trial was to
evaluate long-term effectiveness of perhexiline in angina
pectoris, as well as to establish any side-effects or
complications.
PATIENTS AND METHODS
Twenty-two patients with a history of angina pectoris
of at least 6 months' duration were studied. There were 15
males (12 White, 2 Coloured and 1 Indian) and 7
females (5 White and 2 Coloured). One patient died
after 4 months due to congestive cardiac failure and
is not included in the analysis. Ages ranged from 46 to
78 years (Table I).
No patient had had a myocardial infarction in the
3 months preceding the study. No patient suffered severe
hypertension, anaemia, hypothyroidism or any other
apparent system disorder. All forms of treatment, apart
from digoxin, diuretics and glyceryl trinitrate (when re-
quired), were discontinued for a period of 2 weeks before
the commencement of the trial. The patients were given
perhexiJine 200 mg b.d. for the entire 6-month period of
assessment. Twelve of the patients had taken part in the
previous crossover trial and'will be referred to as the group
from Trial I. The variables measured in the study
included body weight, pulse rate, blood pressure, number
of anginal attacks per week, nitroglycerin intake per week.
resting and effort ECG, haemoglobin, white blood' cell
count, platelet count, prothrombin index, blood glucose,
blood-urea, uric acid, alkaline phosphatase, urine analysis
and serum glutamic oxalo-acetic transaminase (SGOT).
These studies were performed each month, and at the
same time the patients were given a 28-day diary to record
their daily intake of nitroglycerin tablets and their daily.
number of anginal attacks. The patients were also given the
exact number of perhexiline tablets to last for 28 days and
had to report back and account for any unused tablets.
For statistical analysis as shown in Table I, 3 subgroups
of the 2 I patients were considered.
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TABLE I. AGE OF PATIENTS STUDIED
Patient group
Trial 1 (D-P) Trial (P-D) New Total
Sex
Males 5 3 7 15
Females 0 4 2 6
Age - Mean 55,0 yrs 59,8' yrs 60,4 yrs 58,9' yrs
40 - 49 2 0 1 3
50 - 59 1 3 4 8
60 - 69 2 3 1 6
70 - 79 0 0 3 3
905
D-P (Patients from Trial 1 who were on perhexiline first and then placebo); P-D (Patients from Trial 1 who were on placebo first and
then perhexiline) .
.. One patient's age was not certain.
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in I, and oxprenolol (20 mg t.ds.) in a further case.
In all these patients improvement in anginal symptoms
and reduction in nitroglycerin consumption were obtained
within one month of treatment, and this effect was
maintained during the 6 months of therapy.
At the initial visit ECG abnormalities were detected in
20 of the 21 patients. ST-segment depre"s;on after e50rt
was recorded in 11 and frequent ventricular premature
extrasystoles in 2 patients. At the end of the study there
was less ST-segment depression on effort in 2 patients, and
in a further 4 patients the inverted T waves at rest
became upright. In the 2 patients with ventricular extra-
systoles the arrhythmia disappeared in one and was
reduced in the other.
RESULTS
Anginal Attacks
Fintly there was the group of 5 patients from Trial 1
who had been on the perhexiline-placebo sequence in the
earlier study (D-P). Secondly, there were 7 patients also
from Trial I who had been on the placebo-perhexili!l~·
sequence (P-D), and finally 9 new patients who received
perhexiline for the fiEt time. The main reason for
subdividing the patients was to distinguish any carry-over
effect of perhexiline.
Fou:-teen patients were referred to an ophthalmologist
for full ophthalmological examination including visual
acuity, visual fields, lens examination and ocular tension
studies, before and at the conclusion of the 6-month
period.
Before commencing the 6-month study the 9 new
patients had had an average of 22,2 attacks, group D-P
an average of 16,7, and group P-D 13 attacks of angina
per week.
At the end of the 6 months the new patients were
experiencing only 1,4 attacks of angina per week.
(significance in reduction of attacks P<O,OOI according
to the paired t-test), D-P group 5,2 (significance P<O,OI),
and the P-D group 0,9 (significance P<O,OOl) attack5
(Fig. I).
No significant differences were observed between the
months of treatment. As noted in the previous double-
blind crossover study a decrease in the frequency of
anginal symptoms occurred in the majority of cases and
II of the 21 patient3 were totally asymptomatic. In 9
others the angina was of less severity and only one
reported a deterioration of anginal symptoms. Angina
decubitus was present in 6 of the present series and the
number of their anginal attacks dropped from an average
of 28 to an average of 3 attacks per week. There was ;:tn
associated decrease in nitreglycerin intake and they were
able to return to their normal daily activities.
Of the patients in the present study, 6 had previously
been on beta-adrenergic blocking agents with an inade-
quate response. These agents included propranolol (300-









In these 14 patients no ophthalmological differences
were noted at the end of the period, with the exception
of one, where posterior cortical changes of the lens in
keeping with the patient's age were observed.
Side-Effects
Side-effects were similar to those previously reported,
and no new side-effects were detected. Sixteen patients
had one or more side-effects. In none were the side-effects
of such intensity as to cause withdrawal from the trial.
Dizziness was most frequent and usually occurred within
the first 7 - 10 days of therapy, passing off in all patients
within 4 weeks. Less frequent side-effects were headache
and weakness, which lasted for a few days. In 3 patients
(out of a total of 5), where decreased libido had occurred,
this improved towards the end of the study. In I of 3
patients with impotence, this may have been due to
associated diabetes. Other rare side-effects of a transient
nature included arthralgia, frequency of micturition and
constipation (Table lI).
TABLE 11. SIDE-EFFECTS ENCOUNTERED IN 21 PATIENTS
Symptom No. %
Dizziness 11 52
Weight loss <>2 kg) 11 52
Decreased libido 5 24
Headache 4 19




Arthralgia ... 1 5
No symptoms 5 24
During the 6-month study there was a mean loss of
wei'~ht of 2,9 kg. Six patients lost less than 5 kg, 5 patients
lost between 5 and 10 kg, and 1 exceptional patient
with marked oedema lost 17,7 kg. Approximately two-
thirds of this loss occurred within the first 2 months
However, a weight gain ranging from 0,5 to 3,2 kg occurr-
ed in 7 patients. In 2 patients weight remained unchanged.
On 4 separate oc::as:om, including an initial base line
assessment, haematological evaluations were performed
and no abnormal effects on haemoglobin concentration,
platelet count, white cell count and differential count were
noted.
The prothrombin incex remained unchanged, with the
exception of one case where it dropped to 86~~. No
abnormal change was detected in blood-urea, uric acid,
alkaline phosphatase and blood glucose levels. Urin~
analysis showed no abnormalities.
In 15 patients the SGOT levels remained within normal
lim:ts. However, in 4 patients values rose to between
20 and 40 units (normal less than 20 units), and in 2
the maximum values reached 120 and 90 units respectivelv.
Subsequent to this trial, full liver function te~ts, including
albumin-globulin rat;03, protein electrophoresis, bilirubin,
alkaline phosphatase, creatinine phosphokinase and lactic
• dehydrogenase estimations, as well as liver biopsies, were
all normal and the impression was that the raised SGOT
levels settled in mmt patients and dropped cons'derably
in the others.
CONCLUSION
Statistically significant reductions in the average number
of anginal attacks were recorded over the 6-month period
in all three subgroups studied, half the cases being totally
asymptomatic at the end of the period.
No new side-effects were detected, and the same side-
effects previously recorded' were encountered again. In
only one patient of the group studied were the anginal
attacks not reduced. In no patient was the trial discontinued
because of side-effects or intolerance to the drug.
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